touchONCOLOGY spoke to Prof Misako Nagasaka (University of California Irvine, Detroit, MI, USA) to discuss her presentation at the European Lung Cancer Congress 2022, providing the results of the TRUST-II study, a global phase II study for taletrectinib in ROS1 fusion positive lung cancer and other solid tumours.
Questions
- What is taletrectinib and in what tumours is it indicated? 00:16-01:12
- What were the aims and design of the TRUST-II study? 01:12-02:37
- What were the findings in terms of overall response rate and disease control rate? 02:37-04:03
- What is the safety profile of taletrectinib? 04:03-04:55
- What will be the next steps in the clinical development of taletrectinib? 04:55-05:35
Speaker Disclosure: Misako Nagasaka is a consultant for: AnHeart, Caris Life Sciences and Lilly. She is part of the Advisory Board for: AstraZeneca, Daiichi Sankyo, EMD Serono, Genentech, Janssen, Mirati, Novartis, Pfizer, Regeneron and Silverback. She is a Speaker’s Bureau participant with: Takeda and Blue Print Medicines.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Sophie Nickelson.
Filmed in coverage of the European Lung Cancer Congress 2022
